Is Moderna Stock a Buy?
Portfolio Pulse from
Moderna's stock has dropped 58% in 2024, making it one of the worst performers in the S&P 500. The company faces challenges with weak COVID-19 vaccine sales and slow adoption of its new RSV vaccine.
January 19, 2025 | 10:15 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Moderna's stock has significantly declined by 58% in 2024 due to weak COVID-19 vaccine sales and slow market adoption of its RSV vaccine.
The significant drop in Moderna's stock price is attributed to poor sales performance of its COVID-19 vaccine and the slow adoption of its new RSV vaccine. These factors are critical for investors as they directly impact the company's revenue and market position.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100